Research Analysts Set Expectations for Balchem Q3 Earnings

Balchem Co. (NASDAQ:BCPC) – Sidoti Csr boosted their Q3 2025 EPS estimates for shares of Balchem in a research report issued on Monday, April 28th. Sidoti Csr analyst D. Harriman now forecasts that the basic materials company will post earnings per share of $1.36 for the quarter, up from their previous estimate of $1.30. The consensus estimate for Balchem’s current full-year earnings is $4.64 per share. Sidoti Csr also issued estimates for Balchem’s Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $5.15 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.39 EPS, Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.45 EPS.

A number of other brokerages have also issued reports on BCPC. StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. HC Wainwright set a $180.00 target price on shares of Balchem and gave the stock a “buy” rating in a research note on Monday. Finally, Sidoti raised shares of Balchem to a “hold” rating in a research note on Tuesday, February 25th.

Balchem Price Performance

BCPC opened at $156.55 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average of $163.69 and a 200 day moving average of $166.87. Balchem has a 52-week low of $141.09 and a 52-week high of $186.03. The stock has a market cap of $5.09 billion, a P/E ratio of 39.83, a PEG ratio of 4.41 and a beta of 0.75.

Balchem (NASDAQ:BCPC) last announced its earnings results on Thursday, April 24th. The basic materials company reported $1.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.25 by ($0.03). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The business had revenue of $250.52 million for the quarter, compared to analysts’ expectations of $245.70 million. During the same quarter last year, the firm earned $1.03 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis.

Institutional Investors Weigh In On Balchem

Several large investors have recently modified their holdings of BCPC. Vanguard Group Inc. lifted its holdings in Balchem by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,961,487 shares of the basic materials company’s stock worth $645,703,000 after buying an additional 42,693 shares during the period. Geode Capital Management LLC lifted its stake in shares of Balchem by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 938,504 shares of the basic materials company’s stock worth $153,000,000 after purchasing an additional 9,600 shares during the last quarter. Geneva Capital Management LLC boosted its position in Balchem by 5.1% during the fourth quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company’s stock valued at $133,615,000 after purchasing an additional 39,877 shares in the last quarter. FMR LLC grew its stake in Balchem by 16.0% in the fourth quarter. FMR LLC now owns 576,994 shares of the basic materials company’s stock valued at $94,047,000 after purchasing an additional 79,499 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Balchem by 11.0% in the fourth quarter. JPMorgan Chase & Co. now owns 509,490 shares of the basic materials company’s stock worth $83,044,000 after purchasing an additional 50,504 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.